Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer

Background: A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium – folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium – folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology research and treatment 2001-10, Vol.24 (5), p.457-462
Hauptverfasser: Hartung, G., Hofheinz, R.-D., Wein, A., Riedel, C., Rost, A., Fritze, D., Kreuser, E.-D., Drees, M., Kühnel, J., Hehlmann, R., Queisser, W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 462
container_issue 5
container_start_page 457
container_title Oncology research and treatment
container_volume 24
creator Hartung, G.
Hofheinz, R.-D.
Wein, A.
Riedel, C.
Rost, A.
Fritze, D.
Kreuser, E.-D.
Drees, M.
Kühnel, J.
Hehlmann, R.
Queisser, W.
description Background: A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium – folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium – folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous i.v. administration in combination with 5-FU in one pump. Patients and Methods: From 1997 to 1998, 51 patients [median age 60 (range 24–77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m 2 ) and S-FA (500 mg/m 2 ) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3–54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% CI: 5.8–11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%CI: 10.2–22.8). Among major toxicities, NCICTC grade III/IV diarrhea occurred in 13/51 (25.4%), grade III hand-foot syndrome in 6/51 (11.7%) patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.
doi_str_mv 10.1159/000055126
format Article
fullrecord <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_pubmed_primary_11694772</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11694772</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-ec951e6e2b4e7911ba0989c87c50cfaac86abf3b508a9cb1197b1e9c4f13e7bb3</originalsourceid><addsrcrecordid>eNpt0MFu1DAQBmALUdGq7YEzEhpx4xAaO-skPlYrlq7YUqQt4hiNnQlrmtgr2xHaW9-hr8CT8SSkbFku-DKW5psZ6WfsJc_fcS7VRT49Kbkon7ETIVSZSVGK54d_lR-z8xi_T4oLKetKvWDHnJdqVlXihP38vMFIsFzCOo3tDnwHCF-J7vodiFl25ccAS9eN0XoHP2zagMwW_ejD1EBje0DXwtoOY5_QkR8jrH1rxwF-3T_AwvfWWQOXxrZgHaQNwcKGmLKVdQS3gTAN5NLj1WtKGBOmic997wOZhD3M0RkKZ-yowz7S-VM9ZV8W72_nV9nq5sNyfrnKTFHkKSOjJKeShJ5RpTjXmKtamboyMjcdoqlL1F2hZV6jMppzVWlOysw6XlCldXHK3u73muBjDNQ122AHDLuG581j2M0h7Mm-3tvtqAdq_8mnaCfwag_uMHyjcAB_x9_8t3vz6eMf0GzbrvgNnKGQZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer</title><source>Karger Journals</source><source>MEDLINE</source><creator>Hartung, G. ; Hofheinz, R.-D. ; Wein, A. ; Riedel, C. ; Rost, A. ; Fritze, D. ; Kreuser, E.-D. ; Drees, M. ; Kühnel, J. ; Hehlmann, R. ; Queisser, W.</creator><creatorcontrib>Hartung, G. ; Hofheinz, R.-D. ; Wein, A. ; Riedel, C. ; Rost, A. ; Fritze, D. ; Kreuser, E.-D. ; Drees, M. ; Kühnel, J. ; Hehlmann, R. ; Queisser, W.</creatorcontrib><description>Background: A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium – folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium – folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous i.v. administration in combination with 5-FU in one pump. Patients and Methods: From 1997 to 1998, 51 patients [median age 60 (range 24–77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m 2 ) and S-FA (500 mg/m 2 ) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3–54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% CI: 5.8–11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%CI: 10.2–22.8). Among major toxicities, NCICTC grade III/IV diarrhea occurred in 13/51 (25.4%), grade III hand-foot syndrome in 6/51 (11.7%) patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.</description><identifier>ISSN: 2296-5270</identifier><identifier>ISSN: 0378-584X</identifier><identifier>EISSN: 2296-5262</identifier><identifier>DOI: 10.1159/000055126</identifier><identifier>PMID: 11694772</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - pathology ; Drug Administration Schedule ; Female ; Fluorouracil - administration &amp; dosage ; Fluorouracil - adverse effects ; Follow-Up Studies ; Humans ; Infusions, Intravenous ; Leucovorin - administration &amp; dosage ; Leucovorin - adverse effects ; Male ; Middle Aged ; Neoplasm Staging ; Original Article · Originalarbeit ; Sodium - administration &amp; dosage ; Sodium - adverse effects ; Survival Rate</subject><ispartof>Oncology research and treatment, 2001-10, Vol.24 (5), p.457-462</ispartof><rights>2001 S. Karger GmbH, Freiburg</rights><rights>Copyright 2001 S. Karger GmbH, Freiburg</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-ec951e6e2b4e7911ba0989c87c50cfaac86abf3b508a9cb1197b1e9c4f13e7bb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11694772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hartung, G.</creatorcontrib><creatorcontrib>Hofheinz, R.-D.</creatorcontrib><creatorcontrib>Wein, A.</creatorcontrib><creatorcontrib>Riedel, C.</creatorcontrib><creatorcontrib>Rost, A.</creatorcontrib><creatorcontrib>Fritze, D.</creatorcontrib><creatorcontrib>Kreuser, E.-D.</creatorcontrib><creatorcontrib>Drees, M.</creatorcontrib><creatorcontrib>Kühnel, J.</creatorcontrib><creatorcontrib>Hehlmann, R.</creatorcontrib><creatorcontrib>Queisser, W.</creatorcontrib><title>Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer</title><title>Oncology research and treatment</title><addtitle>Oncol Res Treat</addtitle><description>Background: A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium – folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium – folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous i.v. administration in combination with 5-FU in one pump. Patients and Methods: From 1997 to 1998, 51 patients [median age 60 (range 24–77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m 2 ) and S-FA (500 mg/m 2 ) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3–54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% CI: 5.8–11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%CI: 10.2–22.8). Among major toxicities, NCICTC grade III/IV diarrhea occurred in 13/51 (25.4%), grade III hand-foot syndrome in 6/51 (11.7%) patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorouracil - administration &amp; dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Leucovorin - administration &amp; dosage</subject><subject>Leucovorin - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Original Article · Originalarbeit</subject><subject>Sodium - administration &amp; dosage</subject><subject>Sodium - adverse effects</subject><subject>Survival Rate</subject><issn>2296-5270</issn><issn>0378-584X</issn><issn>2296-5262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MFu1DAQBmALUdGq7YEzEhpx4xAaO-skPlYrlq7YUqQt4hiNnQlrmtgr2xHaW9-hr8CT8SSkbFku-DKW5psZ6WfsJc_fcS7VRT49Kbkon7ETIVSZSVGK54d_lR-z8xi_T4oLKetKvWDHnJdqVlXihP38vMFIsFzCOo3tDnwHCF-J7vodiFl25ccAS9eN0XoHP2zagMwW_ejD1EBje0DXwtoOY5_QkR8jrH1rxwF-3T_AwvfWWQOXxrZgHaQNwcKGmLKVdQS3gTAN5NLj1WtKGBOmic997wOZhD3M0RkKZ-yowz7S-VM9ZV8W72_nV9nq5sNyfrnKTFHkKSOjJKeShJ5RpTjXmKtamboyMjcdoqlL1F2hZV6jMppzVWlOysw6XlCldXHK3u73muBjDNQ122AHDLuG581j2M0h7Mm-3tvtqAdq_8mnaCfwag_uMHyjcAB_x9_8t3vz6eMf0GzbrvgNnKGQZQ</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Hartung, G.</creator><creator>Hofheinz, R.-D.</creator><creator>Wein, A.</creator><creator>Riedel, C.</creator><creator>Rost, A.</creator><creator>Fritze, D.</creator><creator>Kreuser, E.-D.</creator><creator>Drees, M.</creator><creator>Kühnel, J.</creator><creator>Hehlmann, R.</creator><creator>Queisser, W.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20011001</creationdate><title>Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer</title><author>Hartung, G. ; Hofheinz, R.-D. ; Wein, A. ; Riedel, C. ; Rost, A. ; Fritze, D. ; Kreuser, E.-D. ; Drees, M. ; Kühnel, J. ; Hehlmann, R. ; Queisser, W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-ec951e6e2b4e7911ba0989c87c50cfaac86abf3b508a9cb1197b1e9c4f13e7bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorouracil - administration &amp; dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Leucovorin - administration &amp; dosage</topic><topic>Leucovorin - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Original Article · Originalarbeit</topic><topic>Sodium - administration &amp; dosage</topic><topic>Sodium - adverse effects</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hartung, G.</creatorcontrib><creatorcontrib>Hofheinz, R.-D.</creatorcontrib><creatorcontrib>Wein, A.</creatorcontrib><creatorcontrib>Riedel, C.</creatorcontrib><creatorcontrib>Rost, A.</creatorcontrib><creatorcontrib>Fritze, D.</creatorcontrib><creatorcontrib>Kreuser, E.-D.</creatorcontrib><creatorcontrib>Drees, M.</creatorcontrib><creatorcontrib>Kühnel, J.</creatorcontrib><creatorcontrib>Hehlmann, R.</creatorcontrib><creatorcontrib>Queisser, W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Oncology research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hartung, G.</au><au>Hofheinz, R.-D.</au><au>Wein, A.</au><au>Riedel, C.</au><au>Rost, A.</au><au>Fritze, D.</au><au>Kreuser, E.-D.</au><au>Drees, M.</au><au>Kühnel, J.</au><au>Hehlmann, R.</au><au>Queisser, W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer</atitle><jtitle>Oncology research and treatment</jtitle><addtitle>Oncol Res Treat</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>24</volume><issue>5</issue><spage>457</spage><epage>462</epage><pages>457-462</pages><issn>2296-5270</issn><issn>0378-584X</issn><eissn>2296-5262</eissn><abstract>Background: A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium – folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer. Sodium – folinic acid (S-FA) is a new formulation which, in contrast to CA-FA allows the simultaneous i.v. administration in combination with 5-FU in one pump. Patients and Methods: From 1997 to 1998, 51 patients [median age 60 (range 24–77) years; 38 male, 13 female] with metastatic colorectal cancer were recruited in 5 centers to receive weekly 24-hour infusions of 5-FU (2,600 mg/m 2 ) and S-FA (500 mg/m 2 ) dissolved in one pump for 6 weeks as first-line treatment. The treatment cycle was repeated after a 2-week rest period. Results: 1,178 administrations (median 24, range 3–54) were performed during the study. Out of 51 patients (median follow-up 20.2 months), 2 (3.9%) achieved complete remission (CR), 17 (33.3%) partial remission (PR), and 21 (41.2%) no change (NC). Progressive disease (PD) was observed in 11/51 (21.6%) patients, including 6 patients who did not complete the first cycle. Median time to tumor progression (TTP) was 8.5 months (95% CI: 5.8–11.3). 32/51 (62.7%) patients survived for more than 1 year, the median survival was reached at 16.5 months (95%CI: 10.2–22.8). Among major toxicities, NCICTC grade III/IV diarrhea occurred in 13/51 (25.4%), grade III hand-foot syndrome in 6/51 (11.7%) patients. Grade III/IV stomatitis was observed in 4/51 (7.8%), cardiac toxicity occurred in 2/51 patients (3.9%). Conclusion: Similar to conventional 24-hour 5-FU + CA-FA treatment, the combination with S-FA induced 37.2% objective responses with moderate toxicity. However, TTP seems favorable and the administration of S-FA is convenient, while saving costs and time for the patient in outpatient units.</abstract><cop>Basel, Switzerland</cop><pmid>11694772</pmid><doi>10.1159/000055126</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2296-5270
ispartof Oncology research and treatment, 2001-10, Vol.24 (5), p.457-462
issn 2296-5270
0378-584X
2296-5262
language eng
recordid cdi_pubmed_primary_11694772
source Karger Journals; MEDLINE
subjects Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Drug Administration Schedule
Female
Fluorouracil - administration & dosage
Fluorouracil - adverse effects
Follow-Up Studies
Humans
Infusions, Intravenous
Leucovorin - administration & dosage
Leucovorin - adverse effects
Male
Middle Aged
Neoplasm Staging
Original Article · Originalarbeit
Sodium - administration & dosage
Sodium - adverse effects
Survival Rate
title Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T16%3A43%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20Study%20of%20a%20Weekly%2024-Hour%20Infusion%20with%205-Fluorouracil%20and%20Simultaneous%20Sodium%20%E2%80%93%20Folinic%20Acid%20in%20the%20First-Line%20Treatment%20of%20Metastatic%20Colorectal%20Cancer&rft.jtitle=Oncology%20research%20and%20treatment&rft.au=Hartung,%20G.&rft.date=2001-10-01&rft.volume=24&rft.issue=5&rft.spage=457&rft.epage=462&rft.pages=457-462&rft.issn=2296-5270&rft.eissn=2296-5262&rft_id=info:doi/10.1159/000055126&rft_dat=%3Cpubmed_karge%3E11694772%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11694772&rfr_iscdi=true